Monday, March 17, 2025 | 01:44 AM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Sun Pharma still not out of red; unsecured loan advances among key concerns

Brokerages seem concerned over the whistleblower case and domestic super-stockist distribution structure

Sun Pharma
Premium

FILE PHOTO: A bird flies past the logo of Sun Pharma installed on the facade of its corporate office in Mumbai | Photo: Reuters

Sohini Das Mumbai
Brokerages on Tuesday said that despite Sun Pharmaceutical’s denial on Monday of allegations of insider trading and other corporate governance lapses, some questions remained unanswered. They added that until the market leader reevaluated structures and transactions that weakened investor confidence, these would continue to overshadow the firm’s performance.

The company’s stock on the BSE shed 2.75 per cent on Tuesday, ending the day at Rs 442.8 per share. On Monday, it had fallen 7.5 per cent, following reports over the weekend that the Securities and Exchange Board of India (Sebi) planned to reopen an insider trading case against Sun Pharma.

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in